BioCentury | Feb 8, 2016
Finance

Asset renaissance

...2010 IPO Ph III Funxional Therapeutics Ltd. 2006 2012 Boehringer Ingelheim GmbH acquired exclusive, worldwide rights to Funxional's...
BioCentury | Jul 30, 2012
Company News

Funxional, Boehringer Ingelheim deal

...The companies said Boehringer will acquire exclusive, worldwide rights to Funxional's somatotaxin portfolio. The portfolio's most...
...chronic obstructive pulmonary disease (COPD). Somatotaxins are a class of anti-inflammatory small molecules targeting SSTR. Funxional's...
...from that are emerging from the Cambridge University lab of co-founder and CSO David Grainger. Funxional Therapeutics Ltd....
BioCentury | Jul 30, 2012
Finance

Funxional in form

...Index Ventures' asset-focused investment strategy continues to bear fruit, with last week's somatotaxin deal by Funxional Therapeutics Ltd....
...its asset-centric portfolio. Last week, Boehringer Ingelheim GmbH agreed to acquire exclusive, worldwide rights to Funxional's...
...the C-terminal lactam peptide (CTLP) site on SSTR2, mimicking the anti-inflammatory effects of natural CTLPs. Funxional...
BioCentury | Jul 24, 2012
Company News

Boehringer to acquire Funxional's somatotaxin portfolio

...U.K) and Boehringer Ingelheim GmbH (Ingelheim, Germany) said Boehringer will acquire exclusive, worldwide rights to Funxional's...
...COPD). Somatotaxins are a class of anti-inflammatory small molecules targeting somatostatin receptor 2 (SSTR2) . Funxional's...
BioCentury | Jun 13, 2011
Company News

Xoma management update

...Calif. Business: Antibodies, Endocrine, Autoimmune Hired: Paul Rubin as CMO and VP, formerly CMO of Funxional Therapeutics Ltd....
BioCentury | May 31, 2010
Company News

Funxional board of directors update

Funxional Therapeutics Ltd. , Cambridge, U.K. Business: Inflammation Appointed: Karl Naegler, general partner at Ventech WIR Staff...
BioCentury | May 31, 2010
Financial News

Funxional completes venture financing

Funxional Therapeutics Ltd. , Cambridge, U.K. Business: Inflammation Date completed: 5/26/10 Type: Venture financing Raised: €10 million ($12.5 million) Investors: Ventech; Index Ventures; Novo A/S WIR Staff Inflammation...
BioCentury | May 27, 2010
Financial News

Funxional raises EUR 10 million

...series B round from new investor Ventech and existing investors Index Ventures and Novo A/S. Funxional's...
...inhibitor that has completed Phase I testing for inflammatory conditions. Ventech's Karl Naegler will join Funxional's...
BioCentury | Jan 18, 2010
Clinical News

FX125L: Phase I data

...of once-daily oral FX125L for 7 days were well tolerated with no serious adverse events. Funxional...
...of FX125L were well tolerated with no serious adverse events (see BioCentury, July 13, 2009). Funxional Therapeutics Ltd....
BioCentury | Dec 7, 2009
Finance

Assetcentricity

...40% of Cyrenaic. Another of Index's asset-centric investments on the cusp of key data is Funxional Therapeutics Ltd....
...to run parallel proof of concept trials in asthma, rheumatoid arthritis (RA) and possibly psoriasis. Funxional...
...Cambridge, U.K. Cyrenaic Pharmaceuticals Inc. , Princeton, N.J. Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands Funxional Therapeutics Ltd....
Items per page:
1 - 10 of 14
BioCentury | Feb 8, 2016
Finance

Asset renaissance

...2010 IPO Ph III Funxional Therapeutics Ltd. 2006 2012 Boehringer Ingelheim GmbH acquired exclusive, worldwide rights to Funxional's...
BioCentury | Jul 30, 2012
Company News

Funxional, Boehringer Ingelheim deal

...The companies said Boehringer will acquire exclusive, worldwide rights to Funxional's somatotaxin portfolio. The portfolio's most...
...chronic obstructive pulmonary disease (COPD). Somatotaxins are a class of anti-inflammatory small molecules targeting SSTR. Funxional's...
...from that are emerging from the Cambridge University lab of co-founder and CSO David Grainger. Funxional Therapeutics Ltd....
BioCentury | Jul 30, 2012
Finance

Funxional in form

...Index Ventures' asset-focused investment strategy continues to bear fruit, with last week's somatotaxin deal by Funxional Therapeutics Ltd....
...its asset-centric portfolio. Last week, Boehringer Ingelheim GmbH agreed to acquire exclusive, worldwide rights to Funxional's...
...the C-terminal lactam peptide (CTLP) site on SSTR2, mimicking the anti-inflammatory effects of natural CTLPs. Funxional...
BioCentury | Jul 24, 2012
Company News

Boehringer to acquire Funxional's somatotaxin portfolio

...U.K) and Boehringer Ingelheim GmbH (Ingelheim, Germany) said Boehringer will acquire exclusive, worldwide rights to Funxional's...
...COPD). Somatotaxins are a class of anti-inflammatory small molecules targeting somatostatin receptor 2 (SSTR2) . Funxional's...
BioCentury | Jun 13, 2011
Company News

Xoma management update

...Calif. Business: Antibodies, Endocrine, Autoimmune Hired: Paul Rubin as CMO and VP, formerly CMO of Funxional Therapeutics Ltd....
BioCentury | May 31, 2010
Company News

Funxional board of directors update

Funxional Therapeutics Ltd. , Cambridge, U.K. Business: Inflammation Appointed: Karl Naegler, general partner at Ventech WIR Staff...
BioCentury | May 31, 2010
Financial News

Funxional completes venture financing

Funxional Therapeutics Ltd. , Cambridge, U.K. Business: Inflammation Date completed: 5/26/10 Type: Venture financing Raised: €10 million ($12.5 million) Investors: Ventech; Index Ventures; Novo A/S WIR Staff Inflammation...
BioCentury | May 27, 2010
Financial News

Funxional raises EUR 10 million

...series B round from new investor Ventech and existing investors Index Ventures and Novo A/S. Funxional's...
...inhibitor that has completed Phase I testing for inflammatory conditions. Ventech's Karl Naegler will join Funxional's...
BioCentury | Jan 18, 2010
Clinical News

FX125L: Phase I data

...of once-daily oral FX125L for 7 days were well tolerated with no serious adverse events. Funxional...
...of FX125L were well tolerated with no serious adverse events (see BioCentury, July 13, 2009). Funxional Therapeutics Ltd....
BioCentury | Dec 7, 2009
Finance

Assetcentricity

...40% of Cyrenaic. Another of Index's asset-centric investments on the cusp of key data is Funxional Therapeutics Ltd....
...to run parallel proof of concept trials in asthma, rheumatoid arthritis (RA) and possibly psoriasis. Funxional...
...Cambridge, U.K. Cyrenaic Pharmaceuticals Inc. , Princeton, N.J. Eurand N.V. (NASDAQ:EURX), Amsterdam, the Netherlands Funxional Therapeutics Ltd....
Items per page:
1 - 10 of 14